Clinical Policy: Pancrelipase (Pertyze, Viokace, Zenpep)
Reference Number: CP.PMN.226
Effective Date: 01.01.20
Last Review Date: 11.20
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Pancrelipase is a combination of porcine-derived lipases, proteases, and amylases.

FDA Approved Indication(s)
- Pancrelipase (Pertyze®, Zenpep®) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
- Pancrelipase (Viokace™), in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Pertyze, Viokace, and Zenpep is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Pancreatic Insufficiency (must meet all):
      1. Diagnosis of exocrine pancreatic insufficiency;
      2. Failure of Creon® and Pancreaze®, unless both are contraindicated or clinically significant adverse effects are experienced;
      3. If request is for Viokace®, both of the following (a and b):
         a. Age ≥ 18 years;
         b. Viokace is prescribed concurrently with a proton pump inhibitor;
      4. Dose does not exceed 2,500 lipase units/kg/meal or 4,000 lipase units/g of fat ingested per day.

   Approval duration: 12 months

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

II. Continued Therapy
   A. Pancreatic Insufficiency (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 2,500 lipase units/kg/meal or 4,000 lipase units/g of fat ingested per day.

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   **Approval duration: Duration of request or 12 months (whichever is less); or**
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

**A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.**

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug*</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>pancrelipase (Creon®)</td>
<td><strong>Infants (up to 12 months)</strong>&lt;br&gt;• 3,000 lipase units (1 capsule) per 120 mL of formula or per breast-feeding. Do not mix capsule contents directly into formula or breast milk prior to administration.</td>
<td>Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines: 2,500 lipase units/kg/meal or 4,000 lipase units/g of fat ingested per day.</td>
</tr>
<tr>
<td></td>
<td><strong>Children &gt; 12 Months and &lt; 4 Years</strong>&lt;br&gt;• Begin with 1,000 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤ 10,000 lipase units/kg of body weight per day), or &lt; 4,000 lipase units/g of fat ingested per day.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children ≥ 4 years and Adults ≥ 18 years</strong>&lt;br&gt;• Begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤ 10,000 lipase units/kg of body weight per day), or &lt; 4,000 lipase units/g of fat ingested per day.</td>
<td></td>
</tr>
</tbody>
</table>
**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertyze (pancrelipase)</td>
<td><strong>Infants (up to 12 months)</strong></td>
<td>Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines: 2,500 lipase units/kg/meal or 4,000 lipase units/g of fat</td>
</tr>
</tbody>
</table>

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*Each agent is not interchangeable with any other pancrelipase product.*

None reported.
### Drug Name | Dosing Regimen | Maximum Dose
--- | --- | ---
**Viokace** (pancrelipase) | *Adults ≥ 18 years* Begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤ 10,000 lipase units/kg of body weight per day), or < 4,000 lipase units/g fat ingested per day. | of body weight per day), or < 4,000 lipase units/g fat ingested per day.

**Zenpep** (pancrelipase) | *Infants (up to 12 months)* • 3,000 lipase units (1 capsule) per 120 mL of formula or per breast-feeding. Do not mix capsule contents directly into formula or breast milk prior to administration. *Children > 12 Months and < 4 Years* • Begin with 1,000 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤ 10,000 lipase units/kg of body weight per day), or < 4,000 lipase units/g fat ingested per day. *Children ≥ 4 years and Adults ≥ 18 years* • Begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or ≤ 10,000 lipase units/kg of body weight per day), or < 4,000 lipase units/g fat ingested per day. | *Each agent is not interchangeable with any other pancrelipase product*

### VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pertyze</strong> (pancrelipase)</td>
<td>Delayed-release capsules: • 4,000 USP units of lipase; 14,375 USP units of protease; 15,125 USP units of amylase • 8,000 USP units of lipase; 28,750 USP units of protease; 30,250 USP units of amylase • 16,000 USP units of lipase; 57,500 USP units of protease; 60,500 USP units of amylase • 24,000 USP units of lipase; 86,250 USP units of protease; 90,750 USP units of amylase</td>
</tr>
<tr>
<td><strong>Viokace</strong> (pancrelipase)</td>
<td>Tablets: • 10,440 USP units of lipase; 39,150 USP units of protease; 39,150 USP units of amylase • 20,880 USP units of lipase; 78,300 USP units of protease; 78,300 USP units of amylase</td>
</tr>
<tr>
<td><strong>Zenpep</strong> (pancrelipase)</td>
<td>Capsules:</td>
</tr>
</tbody>
</table>
Pancrelipase

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 3,000 USP units of lipase; 10,000 USP units of protease; 14,000 USP units of amylase capsules have a white opaque cap and white opaque body, red imprint with “APTALIS 3”</td>
<td></td>
</tr>
<tr>
<td>• 5,000 USP units of lipase; 17,000 USP units of protease; 24,000 USP units of amylase capsules have a white opaque cap and white opaque body, blue imprint with “APTALIS 5”</td>
<td></td>
</tr>
<tr>
<td>• 10,000 USP units of lipase; 32,000 USP units of protease; 42,000 USP units of amylase capsules have a yellow opaque cap and white opaque body, blue imprint with “APTALIS 10”</td>
<td></td>
</tr>
<tr>
<td>• 15,000 USP units of lipase; 47,000 USP units of protease; 63,000 USP units of amylase capsules have a red opaque cap and white opaque body, blue imprint with “APTALIS 15”</td>
<td></td>
</tr>
<tr>
<td>• 20,000 USP units of lipase; 63,000 USP units of protease; 84,000 USP units of amylase capsules have a green opaque cap and white opaque body, blue imprint with “APTALIS 20”</td>
<td></td>
</tr>
<tr>
<td>• 25,000 USP units of lipase; 79,000 USP units of protease; 105,000 USP units of amylase capsules have a blue opaque cap and white opaque body, blue imprint with “APTALIS 25”</td>
<td></td>
</tr>
<tr>
<td>• 40,000 USP units of lipase; 126,000 USP units of protease; 168,000 USP units of amylase capsules have an orange opaque cap and white opaque body, blue imprint with “APTALIS 40”</td>
<td></td>
</tr>
</tbody>
</table>

VII. References
Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.